A SMALL but growing proportion of children under the age of 12 with obesity are being prescribed GLP-1 drugs to help them lose weight. There are signs that this successfully treats obesity, but there are also concerns about the drugs’ long-term effects. So, is this trend likely to continue, and should it? Last month, a study led by Babak Orandi at New York University found that 9.3 per cent of children in the US aged 8 to 11 with obesity but without diabetes are being prescribed GLP-1 drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) – up from 0.03 per cent in 2019. …